| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Shigemi Yoshihara, Hiroshi Morimoto, Makoto Ohori, Yumi Yamada, Toshio Abe, Osamu Arisak. Cannabinoid receptor agonists inhibit Ca(2+) influx to synaptosomes from rat brain. Pharmacology. vol 76. issue 4. 2006-09-27. PMID:16446560. |
only a cannabinoid cb1 antagonist, [n-(piperidin-1-yl)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1h-pyrazole-3-carboxamidehydrochloride] (sr 141716a), reversed the inhibitory effect of these win 55212-2 and anandamide on (45)ca(2+) uptake in rat synaptosomes, but not a cannabinoid cb2 receptor antagonist, [n-[(1s)-endo-1,3,3-trimethylbicyclo[2.2.1]heptan-2-yl]-5-(4-chloro-3-methylphenyl)-1-(4-methylbenzyl)pyrazole-3-carboxamide] (sr 144528). |
2006-09-27 |
2023-08-12 |
rat |
| David Fernández-López, José Martínez-Orgado, Estefanía Nuñez, Julián Romero, Pedro Lorenzo, Maria Angeles Moro, Ignacio Lizasoai. Characterization of the neuroprotective effect of the cannabinoid agonist WIN-55212 in an in vitro model of hypoxic-ischemic brain damage in newborn rats. Pediatric research. vol 60. issue 2. 2006-09-25. PMID:16864698. |
ogd slices were incubated with vehicle or with the cb1/cb2 cannabinoid agonist win55212 (50 microm), the cb1 agonist arachidonyl-2-chloroethylamide (acea) (50 microm), or the cb2 agonist jw133 (50 microm), alone or combined with the cb1 and cb2 receptor antagonist sr 141716 (50 microm) or sr 144528 (50 microm), respectively. |
2006-09-25 |
2023-08-12 |
rat |
| J Singh, S Budhiraj. Therapeutic potential of cannabinoid receptor ligands: current status. Methods and findings in experimental and clinical pharmacology. vol 28. issue 3. 2006-09-11. PMID:16810344. |
there are at least two types of cannabinoid receptors, cb1 also named cnr1 and cb2 also named cnr2, both coupled to g proteins. |
2006-09-11 |
2023-08-12 |
Not clear |
| Janka Held-Feindt, Lutz Dörner, Gülcan Sahan, H Maximilian Mehdorn, Rolf Mentlei. Cannabinoid receptors in human astroglial tumors. Journal of neurochemistry. vol 98. issue 3. 2006-09-08. PMID:16893424. |
these effects have been claimed to be mediated via cannabinoid receptors 1 and 2 (cb1, cb2). |
2006-09-08 |
2023-08-12 |
human |
| Fatima Teixeira-Clerc, Boris Julien, Pascale Grenard, Jeanne Tran Van Nhieu, Vanessa Deveaux, Liying Li, Valérie Serriere-Lanneau, Catherine Ledent, Ariane Mallat, Sophie Lotersztaj. CB1 cannabinoid receptor antagonism: a new strategy for the treatment of liver fibrosis. Nature medicine. vol 12. issue 6. 2006-09-07. PMID:16715087. |
we recently showed that activation of hepatic cannabinoid cb2 receptors limits progression of experimental liver fibrosis. |
2006-09-07 |
2023-08-12 |
mouse |
| Susanna M Saario, Antti Poso, Risto O Juvonen, Tomi Järvinen, Outi M H Salo-Ahe. Fatty acid amide hydrolase inhibitors from virtual screening of the endocannabinoid system. Journal of medicinal chemistry. vol 49. issue 15. 2006-08-31. PMID:16854070. |
the endocannabinoid system consists of two cannabinoid receptors (cb1 and cb2), endogenous ligands (endocannabinoids), and the enzymes involved in the metabolism of the endocannabinoids, including fatty acid amide hydrolase (faah) and monoglyceride lipase (mgl). |
2006-08-31 |
2023-08-12 |
human |
| Matthew J McFarland, Ekaterina A Terebova, Eric L Barke. Detergent-resistant membrane microdomains in the disposition of the lipid signaling molecule anandamide. The AAPS journal. vol 8. issue 1. 2006-08-18. PMID:16584138. |
the endogenous cannabinoid anandamide is an agonist of the cannabinoid receptors cb1 and cb2, as well as transient receptor potential vanilloid type 1 and type 4 ion channels. |
2006-08-18 |
2023-08-12 |
Not clear |
| Ken Mackie, Nephi Stell. Cannabinoid receptors and endocannabinoids: evidence for new players. The AAPS journal. vol 8. issue 2. 2006-08-11. PMID:16796380. |
here we review the evidence suggesting that cannabinoids can modulate synaptic transmission, the cardiovascular system, and the immune system through receptors distinct from cb1 and cb2, and that an additional "independent" endocannabinoid signaling system that involves palmitoylethanolamide may exist. |
2006-08-11 |
2023-08-12 |
Not clear |
| Blanca Herrera, Arkaitz Carracedo, María Diez-Zaera, Teresa Gómez del Pulgar, Manuel Guzmán, Guillermo Velasc. The CB2 cannabinoid receptor signals apoptosis via ceramide-dependent activation of the mitochondrial intrinsic pathway. Experimental cell research. vol 312. issue 11. 2006-08-04. PMID:16624285. |
delta9-tetrahydrocannabinol and other cannabinoids exert pro-apoptotic actions in tumor cells via the cb2 cannabinoid receptor. |
2006-08-04 |
2023-08-12 |
human |
| Blanca Herrera, Arkaitz Carracedo, María Diez-Zaera, Teresa Gómez del Pulgar, Manuel Guzmán, Guillermo Velasc. The CB2 cannabinoid receptor signals apoptosis via ceramide-dependent activation of the mitochondrial intrinsic pathway. Experimental cell research. vol 312. issue 11. 2006-08-04. PMID:16624285. |
cannabinoid treatment led to a cb2 receptor-dependent stimulation of ceramide biosynthesis and inhibition of this pathway prevented delta9-tetrahydrocannabinol-induced mitochondrial hypopolarization and cytochrome c release, indicating that ceramide acts at a pre-mitochondrial level. |
2006-08-04 |
2023-08-12 |
human |
| K A Takahashi, P E Castill. The CB1 cannabinoid receptor mediates glutamatergic synaptic suppression in the hippocampus. Neuroscience. vol 139. issue 3. 2006-08-03. PMID:16527424. |
of the two cloned cannabinoid receptors, cannabinoid receptor 1 (cb1) is widely distributed in the cns and accounts for most of the neurological effects of cannabinoids, while cannabinoid receptor 2 (cb2) expression in the cns is very limited. |
2006-08-03 |
2023-08-12 |
mouse |
| K A Takahashi, P E Castill. The CB1 cannabinoid receptor mediates glutamatergic synaptic suppression in the hippocampus. Neuroscience. vol 139. issue 3. 2006-08-03. PMID:16527424. |
cannabinoid receptor 3 (cb3)] is suggested by growing evidence of cannabinoid effects that are not mediated by cb1 or cb2. |
2006-08-03 |
2023-08-12 |
mouse |
| Seishi Kishimoto, Saori Oka, Maiko Gokoh, Takayuki Sugiur. Chemotaxis of human peripheral blood eosinophils to 2-arachidonoylglycerol: comparison with other eosinophil chemoattractants. International archives of allergy and immunology. vol 140 Suppl 1. 2006-08-03. PMID:16772720. |
2-arachidonoylglycerol (2-ag), an endogenous ligand for the cannabinoid receptors (cb1 and cb2), has been shown to exhibit a variety of cannabimimetic activities in vitro and in vivo. |
2006-08-03 |
2023-08-12 |
human |
| Spiro Pavlopoulos, Ganesh A Thakur, Spyros P Nikas, Alexandros Makriyanni. Cannabinoid receptors as therapeutic targets. Current pharmaceutical design. vol 12. issue 14. 2006-08-01. PMID:16712486. |
the cannabinoid receptors cb1 and cb2 are family a, g-protein coupled receptors that mediate the effects of cannabinoids, a class of compounds that are so named because the first members were isolates of the cannabis plant. |
2006-08-01 |
2023-08-12 |
Not clear |
| Erica J Carrier, John A Auchampach, Cecilia J Hillar. Inhibition of an equilibrative nucleoside transporter by cannabidiol: a mechanism of cannabinoid immunosuppression. Proceedings of the National Academy of Sciences of the United States of America. vol 103. issue 20. 2006-07-28. PMID:16672367. |
the plant-derived cannabinoids delta9-tetrahydrocannabinol (thc) and cannabidiol (cbd) both have immunosuppressive effects; although some effects of thc are mediated by the cb2 receptor, cb2 binds cbd weakly. |
2006-07-28 |
2023-08-12 |
mouse |
| Jean-Sébastien Walczak, Vincent Pichette, François Leblond, Karine Desbiens, Pierre Beaulie. Characterization of chronic constriction of the saphenous nerve, a model of neuropathic pain in mice showing rapid molecular and electrophysiological changes. Journal of neuroscience research. vol 83. issue 7. 2006-07-25. PMID:16511871. |
these behavioral changes were accompanied after surgery by an increase of c-fos expression and by an overexpression of mu-opioid and cannabinoid cb1 and cb2 receptors in the spinal cord and the dorsal hind paw skin. |
2006-07-25 |
2023-08-12 |
mouse |
| Stefan Raduner, Adriana Majewska, Jian-Zhong Chen, Xiang-Qun Xie, Jacques Hamon, Bernard Faller, Karl-Heinz Altmann, Jürg Gertsc. Alkylamides from Echinacea are a new class of cannabinomimetics. Cannabinoid type 2 receptor-dependent and -independent immunomodulatory effects. The Journal of biological chemistry. vol 281. issue 20. 2006-07-21. PMID:16547349. |
alkylamides (alkamides) from echinacea modulate tumor necrosis factor alpha mrna expression in human monocytes/macrophages via the cannabinoid type 2 (cb2) receptor (gertsch, j., schoop, r., kuenzle, u., and suter, a. |
2006-07-21 |
2023-08-12 |
human |
| Stefan Raduner, Adriana Majewska, Jian-Zhong Chen, Xiang-Qun Xie, Jacques Hamon, Bernard Faller, Karl-Heinz Altmann, Jürg Gertsc. Alkylamides from Echinacea are a new class of cannabinomimetics. Cannabinoid type 2 receptor-dependent and -independent immunomodulatory effects. The Journal of biological chemistry. vol 281. issue 20. 2006-07-21. PMID:16547349. |
here we show that the alkylamides dodeca-2e,4e,8z,10z-tetraenoic acid isobutylamide (a1) and dodeca-2e,4e-dienoic acid isobutylamide (a2) bind to the cb2 receptor more strongly than the endogenous cannabinoids. |
2006-07-21 |
2023-08-12 |
human |
| Stefan Raduner, Adriana Majewska, Jian-Zhong Chen, Xiang-Qun Xie, Jacques Hamon, Bernard Faller, Karl-Heinz Altmann, Jürg Gertsc. Alkylamides from Echinacea are a new class of cannabinomimetics. Cannabinoid type 2 receptor-dependent and -independent immunomodulatory effects. The Journal of biological chemistry. vol 281. issue 20. 2006-07-21. PMID:16547349. |
the ki values of a1 and a2 (cb2 approximately 60 nm; cb1 >1500 nm) were determined by displacement of the synthetic high affinity cannabinoid ligand [3h]cp-55,940. |
2006-07-21 |
2023-08-12 |
human |
| Stefan Raduner, Adriana Majewska, Jian-Zhong Chen, Xiang-Qun Xie, Jacques Hamon, Bernard Faller, Karl-Heinz Altmann, Jürg Gertsc. Alkylamides from Echinacea are a new class of cannabinomimetics. Cannabinoid type 2 receptor-dependent and -independent immunomodulatory effects. The Journal of biological chemistry. vol 281. issue 20. 2006-07-21. PMID:16547349. |
at 50 nm, a1, a2, and the endogenous cannabinoid anandamide (cb2 ki >200 nm) up-regulated constitutive interleukin (il)-6 expression in human whole blood in a seemingly cb2-dependent manner. |
2006-07-21 |
2023-08-12 |
human |